A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 32
Summary
- Conditions
- Multiple Myeloma
- Non Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Tracking Information
- NCT #
- NCT02078102
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Sherif Farag, M.D., Ph.D. Indiana University
- Sherif Farag, M.D., Ph.D. Indiana University
Get Well Soon